Details

Autor(en) / Beteiligte

• Valgimigli, Marco
• Frigoli, Enrico
• Leonardi, Sergio
• Rothenbühler, Martina
• Gagnor, Andrea
• Calabrò, Paolo
• Garducci, Stefano
• Rubartelli, Paolo
• Briguori, Carlo
• Andò, Giuseppe
• Repetto, Alessandra
• Limbruno, Ugo
• Garbo, Roberto
• Sganzerla, Paolo
• Russo, Filippo
• Lupi, Alessandro
• Cortese, Bernardo
• Ausiello, Arturo
• Ierna, Salvatore
• Esposito, Giovanni
• Presbitero, Patrizia
• Santarelli, Andrea
• Sardella, Gennaro
• Varbella, Ferdinando
• Tresoldi, Simone
• de Cesare, Nicoletta
• Rigattieri, Stefano
• Zingarelli, Antonio
• Tosi, Paolo
• van ’t Hof, Arnoud
• Boccuzzi, Giacomo
• Omerovic, Elmir
• Sabaté, Manel
• Heg, Dik
• Jüni, Peter
• Vranckx, Pascal

Titel

Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes

Ist Teil von

• The New England journal of medicine, 2015-09, Vol.373 (11), p.997-1009

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• In 7213 patients with an acute coronary syndrome, the rate of major adverse cardiovascular events was not significantly lower with bivalirudin than with heparin. Post-PCI bivalirudin infusion did not reduce the risk of stent thrombosis. The most effective antithrombotic regimen for preventing ischemic complications while limiting bleeding risk in patients with an acute coronary syndrome who are undergoing invasive treatment remains unknown. 1 – 3 Two of the most commonly used antithrombotic regimens worldwide 4 , 5 are unfractionated heparin, an indirect thrombin inhibitor, with or without the concomitant use of a glycoprotein IIb/IIIa inhibitor, and bivalirudin, a direct thrombin inhibitor, with a glycoprotein IIb/IIIa inhibitor added only for periprocedural ischemic complications. Previous studies that have compared these two options among patients who were undergoing invasive treatment for an acute coronary syndrome have provided conflicting results with respect to . . .